Rap1 Affects the Length and Heterogeneity of Human Telomeres

Bibo Li and Titia de Lange*

The Rockefeller University, New York, New York 10021

Submitted June 16, 2003; Revised August 7, 2003; Accepted August 8, 2003

Monitoring Editor: Joseph Gall

Telomere length is controlled in part by cis-acting negative regulators that limit telomere extension by telomerase. In budding yeast, the major telomere length regulator scRap1 binds to telomeric DNA and acts to inhibit telomere elongation in cis. Because the human Rap1 ortholog hRap1 does not bind to telomeric DNA directly but is recruited to telomeres by TRF2, we examined its role in telomere length control. The data are consistent with hRap1 being a negative regulator of telomere length, indicating functional conservation. Deletion mapping confirmed that hRap1 is tethered to telomeres through interaction of its C terminus with TRF2. The telomere length phenotypes of hRap1 deletion mutants implicated both the BRCT and Myb domain as protein interaction domains involved in telomere length regulation. By contrast, scRap1 binds to telomeres with its Myb domains and uses its C terminus to recruit the telomere length regulators Rif1 and Rif2. Together, our data show that although the role of Rap1 at telomeres has been largely conserved, the domains of Rap1 have undergone extensive functional changes during eukaryotic evolution. Surprisingly, hRap1 alleles lacking the BRCT domain diminished the heterogeneity of human telomeres, indicating that hRap1 also plays a role in the regulation of telomere length distribution.

INTRODUCTION

The maintenance of human telomeres is regulated at two levels. The primary control of telomere maintenance takes place at the level of telomerase expression. Repression of telomerase in the soma leads to programmed telomere shortening, and this process can limit the replicative lifespan of primary human cells. However, in the germ line and in immortal human cells, telomerase is active and counteracts telomere attrition. Such cells display a second level of control that results in stable maintenance of all telomeres within a limited size range. This telomere length homeostasis is achieved through a negative feedback loop involving cis-acting regulators of telomerase-mediated telomere extension (van Steensel and de Lange, 1997; Kim et al., 1999; Smith and de Lange, 2000; Smogorzewska et al., 2000; Ancelin et al., 2002; Loayza and de Lange, 2003). These negative regulators accumulate along the duplex telomeric repeat array, and their presence at chromosome ends results in increasing inhibition of telomerase as telomeres become elongated.

Studies in yeast and human cells indicate that the principles of telomere length homeostasis are similar in diverged eukaryotes (McCachern and Blackburn, 1995; Krauskopf and Blackburn, 1996; Marcard et al., 1997a; van Steensel and de Lange, 1997). However, the telomeric protein complex responsible for negative length regulation has undergone drastic changes in its composition. A main player in human telomere length homeostasis is the TRF1 complex, composed of the duplex telomeric repeat binding factor TRF1, and its associated proteins tankyrase 1 and 2, hTIN2, hPot1, and PINX1 (Chong et al., 1995; Smith et al., 1998; Kim et al., 1999; Kaminker et al., 2001; Zhou and Lu, 2001; Loayza and de Lange, 2003). In Saccharomyces cerevisiae, an entirely different set of proteins, the telomeric binding protein Rap1, and its interacting factors Rif1 and Rif2, form the major telomere length regulatory complex (Hardy et al., 1992; Marcard et al., 1997b; Wotton and Shore, 1997). Remarkably, there is no TRF-like factor bound to budding yeast telomeres, and the genes for tankyrases and TIN2 seem to be absent from the budding yeast genome.

The human genome encodes a distant ortholog of S. cerevisiae Rap1, hRap1, which differs from its yeast counterpart in that it lacks the ability to directly bind to telomeric DNA (Li et al., 2000; Hanaoka et al., 2001). Instead, hRap1 is recruited to telomeres through interaction with TRF2, a TRF1 paralog (reviewed in de Lange, 2002). The mammalian version of the telomeric complex is likely to represent the ancestral telomere type because Schizosaccharomyces pombe Rap1 also lacks telomeric DNA binding activity and is recruited to telomeres through an interaction with Taz1, which is related to TRF2 both structurally and functionally (Cooper et al., 1997; Chikashige and Hiraoka, 2001; Kanoh and Ishikawa, 2001; de Lange, 2002). Despite these extensive rearrangements within the telomeric complex, Rap1 acts as a negative regulator of telomere length in both fission yeast and two budding yeasts (Conrad et al., 1990; Lustig et al., 1990; Krauskopf and Blackburn, 1996; Marcard et al., 1997a,b; Chikashige and Hiraoka, 2001; Kanoh and Ishikawa, 2001). Here, we further extend the study of these parallels in telomere length regulation and examine the role of hRap1 in telomere length control.

MATERIALS AND METHODS

Retroviral Expression Constructs

A BamHI fragment of hRap1 full-length cDNA was inserted into the BamHI site of pLPC to generate a retroviral construct expressing full-length hRap1.
protein. For hRap1 deletion mutant, a FLAG tag (generated by annealing oligos: 5'-GATCTCGCCGACCATTGACTCTAAA-3' and 5'-GATCTTTATCGTATGCTCITGTCATGC-3') was first inserted into pLPC at BamHI site. The BamHI site at the N terminus of the FLAG tag was destroyed by ligation to a BglII site. PCR fragments containing different hRap1 deletions were generated, digested with BglII, and inserted in frame 3 of the FLAG tag.

**Retroviral Infection and Selection**

Retroviral gene delivery was performed as described previously (Karlseder et al., 2002). Phoenix amphotropic retroviral packaging cells were transfected with retroviruses containing different alleles of hRap1. At 24, 32, and 48 h posttransfection, HTC75, IMR90, and HeLa1.2.11 cells were incubated with the virus-containing medium with 4 μg/ml polybrene. Sixteen hours after the last infection, puromycin selection (2 μg/ml) was started and maintained for 5–7 days. The plating efficiency was around 10% for HTC75, IMR90, and GM487 cells and ~20% in HeLa1.2.11 cells. Cells were maintained in DMEM medium with 10% (HTC75 and GM487) or 15% (IMR90) fetal bovine serum or 10% bovine calf serum (HeLa1.2.11). Cells were infected at passage 13 (population doubling [PD]30) and the selection lasted for 3–4 PD. Each passage of IMR90 represents a 1:3 split of cells. For telomere elongation experiments in HTC75 and GM487 cells, P0 was arbitrarily set after infected cells reached 80% confluence after the first split into four 10-cm dishes. All cell populations went through approximately the same number of divisions before reaching “P0.”

**Telomere Length Analysis**

Cells from a subconfluent 15-cm dish were trypsinized, washed in cold 1× phosphate-buffered saline (PBS). DNA was isolated from the cell pellet as described previously (de Lange et al., 1996) with inclusion of an RNase-A digestion step. DNA from HTC75 and IMR90 cells was digested with HinfI/RsaI, and genomic blotting for telomeric fragments was carried out according to standard protocols (van Steensel and de Lange, 1997). For telomere length analysis in GM487 cells, DNA was isolated from cells embedded in agarose plugs. DNA embedded in agarose plugs was digested with MboI/AatII and electrophoresed through 1% agarose gels in 0.5× Tris borate-EDTA main- tained at 13°C, by using a CHEF DR-II pulsed-field apparatus (Bio-Rad, Hercules, CA). Separation was for 18 h at 58 V/cm at a constant pulse time of 5 s. In-gel hybridization was carried out using an end-labeled (CCCTAA)n oligo as described previously (Karlseder et al., 2002) after in situ denaturation of the DNA. Telomere blots or gels were exposed to PhosphorImager screens for 24 h.

The data was analyzed by ImageQuant and Microsoft Excel. Mean telomeric restriction fragment lengths were calculated assuming a Gaussian distribution. Because of the presence of subtelomeric sequences, the length of the 24-bp TTAGGG repeat region is assumed to be 2 kb shorter than the telomeric restriction fragment length. Telomere length distributions and the telomere length heterogeneity index in Table 2 were determined as follows. The signal intensity was determined over the lane as a function of the distance from the slot. A baseline was used that reflected the slight increase in signal background at higher molecular weight (MW). The accumulative sum of the signal reached 25 and 75% of the total signal were identified and the telomeric restriction fragment sizes corresponding to these positions were calculated based on molecular weight markers. The difference between these MW values is referred to as the 50% signal interval (in kilobases) and functions as a measure for the size distribution of the telomeric signal. The telomere length heterogeneity index is defined as the 50% signal interval (in kilobases) divided by the median telomere length (in kilobases). In control cultures, the heterogeneity index is close to 1. For instance, when the mean telomere length is 3 kb, 50% of the telomeric signal is found in a 3-kb size interval.

**Indirect Immunofluorescence (IF)**

For IF, cells were washed with PBS buffer, fixed with 2% formaldehyde/PBS, and permeabilized with 0.5% NP-40/PBS, followed by antibody incubations as described previously (Smogorzewska et al., 2000). For Triton X-100 extraction experiments, cells were washed with PBS buffer, treated with Triton X-100 buffer (0.5% Triton X-100, 20 mM HEPES, pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose for 5 min at room temperature) and 0.2% formaldehyde/2% sucrose/PBS, and permeabilized with the same Triton X-100 buffer, followed by antibody incubations as described in Zhu et al. (2000). Endogenous and retrovirally expressed full-length hRap1 was de tection with 1:400 rabbit anti-hRap1 serum (Li et al., 2000; TRF1 was detected with a monoclonal mouse anti-TRF1 serum or rabbit 371 anti-hTRF1 serum (van Steensel and de Lange, 1997). hRap1 deletion mutants were detected using anti-FLAG antibody M2 (Sigma-Aldrich, St. Louis, MO).

**Cell Extracts and Western Blotting**

Whole cell extracts were prepared using a modified radioimmunoprecipitation assay buffer (50 mM Tris-Cl, pH 7.4, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 1 mM diithothreitol, 1 mM phenylmethylsulfonyl fluoro- ride, 0.1 mg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml antymyelitin). For Western blotting, 60 μg of protein was separated on SDS/10% PAGE and transferred to nitrocellulose by electrobombing. Membranes were stained with Ponceau S to verify equal amount loading of protein samples. Membranes were then blocked with 1× PBS/10% nonfat dry milk/0.05% Tween 20 at RT for 1 h, probed with primary antibodies in 1× PBS/0.1% Tween 20/0.1% nonfat dry milk at 4°C for 16 h and secondary horseradish peroxidase-conjugated donkey anti-rabbit antibody (for antibodies 371, 647, and 765) or sheep anti-mouse antibody (for antibodies M2 and GTU88) at RT for 30 min. Membranes were washed with the same incubation buffer three times before detecting protein bands using an enhanced chemiluminescence kit (Amer sham Biosciences, Piscataway, NJ). Expression of hRap1 full-length or mutant proteins was detected using 765 rabbit anti-hRap1 serum or M2 monoclonal antibody against FLAG (see above). Endogenous γ-tubulin was detected with monoclonal antibody GTU88 (Sigma-Aldrich). Endogenous TRF1 and TRF2 proteins were detected by rabbit antibodies 371 and 647, respectively.

**RESULTS**

**Subnuclear Localization of hRap1 Deletion Mutants**

Human Rap1 has four domains, a BRCT domain, a Myb HTH motif, a coiled region, and a C-terminal protein interaction domain (termed RCT) (Table 1) (Li et al., 2000). The RCT region is known to be required for binding to TRF2 and mediates the association of hRap1 with telomeres. The functions of the other domains are not known. Myb domains are more commonly involved in DNA binding, but no such activity has been demonstrated for the hRap1 Myb domain and its structure is not well suited for DNA binding (Li et al., 2000; Hanaoka et al., 2001). Therefore, it was proposed that the hRap1 Myb domain may be involved in protein interac- tion as has been shown for several other proteins (Li et al., 2000; Hanaoka et al., 2001). We generated 11 hRap1 deletion mutants lacking one or more of its domains and monitored their expression in human cells that also expressed endog enous (wt) hRap1. Each of the alleles was endowed with an N-terminal FLAG tag, allowing detection of the exogenous protein in IF and immunoblotting. Five hRap1 mutants (two lacking the N-terminal 94 or 184 aa, two lacking the C-termin al 25 or 40 aa; and one triple mutant lacking the BRCT domain, Myb domain, and part of the RCT domain) were expressed at extremely low levels (our unpublished data) and not studied further. The other six hRap1 mutants yielded stably expressed proteins as determined by immuno blotting (Figure 1, A and B). Of some of the stably expressed hRap1 mutants were overexpressed compared with the endogenous protein, whereas others were expressed at a level comparable with or lower than endogenous hRap1 (Figure 1B and Table 1). Similar expression levels were observed in HeLa1.2.11, IMR90, and GM487 cells (our unpublished data). There was no obvious correlation between the expres- sion levels of the various hRap1 alleles and their telomere length phenotype (see below).

The subnuclear localization of the altered hRap1 proteins was determined by IF in two human tumor cell lines, the HT1080-derived line, HTC75, and HeLa1.2.11, a HeLa subclone with long telomeres (van Steensel and de Lange, 1997). Retroviral expression of full-length hRap1, as well as all mutant alleles resulted in a predominantly nucleoplasmic staining pattern in both HTC75 cells and in HeLa1.2.11 (Figure 2; our unpublished data). Because this pattern is likely due to overexpression and saturation of the telomeric hRap1 binding sites, we examined HeLa1.2.11 cells after

Vol. 14, December 2003

5061
extraction of the nucleoplasmic proteins with Triton X-100 (Figure 2). Under these conditions, telomeric association of full-length hRap1 as well as four of the six mutant hRap1 proteins could be demonstrated based on the colocalization with the telomeric protein TRF1, previously shown to be exclusively located at telomeres (Chong et al., 1995). As expected, two hRap1 mutants lacking the C-terminal TRF2 binding domain (hRap1/H9004CT and hRap1/H9004BrCT) were not detectable at telomeres after Triton X-100 extraction, indicating that these alleles were primarily expressed in the nucleoplasm. These results are consistent with previous data indicating that hRap1 depends on its interaction with TRF2 to localize to telomeres (Li et al., 2000) and that other domains, such as the BRCT domain and the Myb domain are not required for the accumulation of hRap1 in the telomeric complex. IF analysis also showed that the hRap1 mutant alleles do not significantly affect the accumulation of TRF1 and TRF2 on telomeres (Figure 2; our unpublished data). In addition, the endogenous protein levels for TRF1 and TRF2 are not affected by expression of exogenous hRap1 alleles (our unpublished data).

The hRap1 interacting partner TRF2 is required for telomere protection (reviewed in de Lange, 2002). Inhibition of TRF2 by using truncation alleles results in partial loss of the telomeric G-strand overhang, telomere fusions, and cell cycle arrest, accompanied by senescence or apoptosis. None of these phenotypes were observed upon expression of the hRap1 mutants, and there was no obvious effect on the viability and growth characteristics of the cells (our unpublished data). This was true both in short-term cultures and upon long-term growth of tumor cell lines and primary human fibroblasts (our unpublished data).

The hRap1 interacting partner TRF2 is required for telomere protection (reviewed in de Lange, 2002). Inhibition of TRF2 by using truncation alleles results in partial loss of the telomeric G-strand overhang, telomere fusions, and cell cycle arrest, accompanied by senescence or apoptosis. None of these phenotypes were observed upon expression of the hRap1 mutants, and there was no obvious effect on the viability and growth characteristics of the cells (our unpublished data). This was true both in short-term cultures and upon long-term growth of tumor cell lines and primary human fibroblasts (our unpublished data).

The hRap1 interacting partner TRF2 is required for telomere protection (reviewed in de Lange, 2002). Inhibition of TRF2 by using truncation alleles results in partial loss of the telomeric G-strand overhang, telomere fusions, and cell cycle arrest, accompanied by senescence or apoptosis. None of these phenotypes were observed upon expression of the hRap1 mutants, and there was no obvious effect on the viability and growth characteristics of the cells (our unpublished data). This was true both in short-term cultures and upon long-term growth of tumor cell lines and primary human fibroblasts (our unpublished data).

**Table 1. Localization and telomere phenotypes of hRap1 deletion mutants**

<table>
<thead>
<tr>
<th>name</th>
<th>structure</th>
<th>localization</th>
<th>telomere length change</th>
<th>telomere heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>pLPC vector</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hRap1-FL</td>
<td></td>
<td>T</td>
<td>-20 (0.014); -7 (0.36)</td>
<td>wt</td>
</tr>
<tr>
<td>hRap1ACT</td>
<td></td>
<td>T</td>
<td>30 (0.97)</td>
<td>wt</td>
</tr>
<tr>
<td>hRap14BrACT</td>
<td></td>
<td>N</td>
<td>30 (0.85); 40 (0.90); 40 (0.95)</td>
<td>wt</td>
</tr>
<tr>
<td>hRap14M</td>
<td></td>
<td>N</td>
<td>30 (0.98); 30 (0.94)</td>
<td>wt</td>
</tr>
<tr>
<td>hRap1AbM</td>
<td></td>
<td>T</td>
<td>60 (0.93); 60 (0.99)</td>
<td>C</td>
</tr>
<tr>
<td>hRap14Mdc</td>
<td></td>
<td>T</td>
<td>60 (0.96); 60 (0.98); 60 (0.92)</td>
<td>c</td>
</tr>
<tr>
<td>hRap14M1C</td>
<td></td>
<td>T</td>
<td>60 (0.94); 70 (0.99)</td>
<td>C</td>
</tr>
<tr>
<td>hRap14M2C</td>
<td></td>
<td>T</td>
<td>80 (0.97)</td>
<td>wt</td>
</tr>
</tbody>
</table>

a Deleted segments are indicated with aa coordinates (inclusive).

b Subnuclear localization was determined in HeLa1.2.11 cells by IF after Triton extraction (see Fig.2). For pLPC, the localization of the endogenous hRAP1 is listed. T, telomeric; N, nucleoplasmic.

c Telomere length changes in HTC75 (in bp/end/PD) were determined during the initial elongation stage at 3 or more PDs. Values from multiple independent experiments are given with the R^2 value. Telomere length changes in the pLPC control are not significant.

d Telomere length heterogeneity was determined by genomic blotting. wt, as in control HTC75 cells. ↓↓↓ strongly diminished telomere length heterogeneity (see Table 2 for detailed description and methods).

**Figure 1.** Immunoblotting analysis of hRap1 alleles. Extracts were prepared from retrovirally infected HTC75 cells expressing the indicated hRap1 alleles, and immunoblots were probed for the FLAG epitope added to the exogenous hRap1 alleles (M2) and γ-tubulin in A or for hRap1 (antibody 765) in B. The arrow in B indicates the position of endogenous hRap1. Asterisks in B mark bands representing the hRap1 mutant proteins. Some mutant proteins show degradation products.
and Table 1) (van Steensel and de Lange, 1997; Li
Control HTC75 cells infected with the retroviral vector have independent pools of infected cells (Figure 3A and Table 1). DNA was stained by 4,6-diamidino-2-phenylindole.

(pD) in several potential sources (reviewed in de Lange, 1995). First, individual cells can have different telomere length settings, but this effect is minimized in clonal cell populations such as the HTC75 cell line used in these studies. Second, the length of the telomere repeat tract can vary between individual chromosomes. Third, each individual telomere is heterogeneous in length even in clonal cell lines (Farr et al., 1991; Hanish et al., 1994). We observed a gradual change in the telomere length heterogeneity in cells expressing hRap1 telomeric hRap1 alleles lacking the BRCT domain (Figure 3A). After ~80 PD the telomeric restriction fragments were considerably less heterogeneous, and they continued to become more discrete over the next 40 PD. Scans of the pertinent lanes confirmed that the size distribution of hRap1 is more narrow than the distribution of hRap1 CT, even though the telomeres have approximately the same mean length (Figure 3B). Similarly, scans of pertinent lanes confirmed that the telomeres of hRap1 CT and hRap1 CT are more narrow than the distribution of hRap1 CT, even though the telomeres have approximately the same mean length (Figure 3B).

Telomeric hRap1 Alleles Lacking the BRCT Domain Diminish Telomere Length Heterogeneity

Restriction fragments representing human telomeres are often very heterogeneous in length. This length variability has several potential sources (reviewed in de Lange, 1995). First, individual cells can have different telomere length settings, but this effect is minimized in clonal cell populations such as the HTC75 cell line used in these studies. Second, the length of the telomere repeat tract can vary between individual chromosomes. Third, each individual telomere is heterogeneous in length even in clonal cell lines (Farr et al., 1991; Hanish et al., 1994). We observed a gradual change in the telomere length heterogeneity in cells expressing hRap1 CT and hRap1 CT (Figure 3A). After ~80 PD the telomeric restriction fragments were considerably less heterogeneous, and they continued to become more discrete over the next 40 PD. Scans of the pertinent lanes confirmed that the size distribution of hRap1 is more narrow than the distribution of hRap1 CT, even though the telomeres have approximately the same mean length (Figure 3B). Similarly, scans of pertinent lanes confirmed that the telomeres of hRap1 CT are more narrow than the distribution of hRap1 CT, even though the telomeres have approximately the same mean length (Figure 3B).

To measure the heterodisperse nature of the telomeric restriction fragment pattern, we compared the size range occupied by 50% of the telomeric hybridization signal and compared this with the median length of the telomeres (the heterogeneity index; see MATERIALS AND METHODS and Table 2). The heterogeneity index for control cells and hRap1 infected cells at PD0 was always close to 1 (mean 1, SD 0.06, n = 5). For instance, control cells with a median telomere length of 2 kb usually showed blots in which 50% of the telomeric signal was spread out over a 2-kb interval. The heterogeneity index did not change during prolonged growth of hRap1 cells (Table 2, compare hRap1 cells at PD0 and PD120), even though the telomeres gradually elongated from 2–4.8 kb. In contrast, cells expressing telomeric hRap1 alleles lacking the BRCT domain showed a significant drop in the heterogeneity index (p = 0.0013). Although these cells started out with a heterogeneity index of close to 1, the index diminished to a mean value of 0.5 (SD 0.02, n = 4) after prolonged culture growth. This reduction is significant (p = 0.01) even compared with the slightly reduced heterogeneity

Figure 2. Subnuclear localization of hRap1 alleles. Top, IF for hRap1 (antibody 765) and TRF1 (detected with a mouse polyclonal) in HTC75 and HeLa1.2.11 cells infected with full-length untagged hRap1 retrovirus. The HeLa1.2.11 cells were extracted with Triton X-100 before IF. Bottom, IF for exogenous hRap1 proteins (M2) was carried out in retrovirally infected HTC75 and Triton-extracted HeLa1.2.11 cells. Telomeric loci are identified based on TRF1 IF (antibody 371). DNA was stained by 4,6-diamidino-2-phenylindole.

wild-type hRap1 is consistent with our previous finding that inducible expression of an N-terminally FLAG-tagged hRap1 allele resulted in a slight increase in telomere length in HTC75 cells (Li et al., 2000).

We next examined the four mutants of hRap1 that had retained the ability to interact with TRF2 and therefore localized to telomeres (hRap1 CT, hRap1 BrCT, hRap1 BrM, and hRap1 BrMCT). These mutants also induced telomere elongation in multiple independent experiments (Figure 3A and Table 1). For these mutants, the elongation rates seemed higher than for full-length hRap1 (60–80 base pairs/end/PD for the mutants versus 30–40 base pairs/end/PD for wild-type hRap1; Table 1). These differences are not attributable to expression levels because these alleles were expressed at relatively low levels (Figure 1).

Two hRap1 mutants that lacked the TRF2 binding domain and did not localize to telomeres, hRap1 BrCT and hRap1 BrMCT, also induced telomere elongation at a rate of ~30 base pairs/end/PD (Figure 3A and Table 1). Thus, the telomere elongation phenotype of overexpression of hRap1 was independent of its ability to localize to telomeres.

Loayza and de Lange, 2003), HTC75 cells were used to study the effects of retrovirally expressed hRap1 alleles. Infected cells were selected with puromycin, and a pool of infected cells was examined for telomere length dynamics by genomic blotting. Although HTC75 cells, like other human tumor cell lines, can display a high degree of variation in telomere length and telomere dynamics, the analysis of large pools of infected cells reduces outlier effects, allowing the analysis of the effect of exogenous proteins on telomere length setting. HTC75 cells overexpressing wild-type hRap1 were found to display a telomere elongation phenotype (initial elongation rate of ~30 base pairs/end/PD) in several independent pools of infected cells (Figure 3A and Table 1) (van Steensel and de Lange, 1997; Li et al., 2000; Smogorzewska et al., 2000). The elongation phenotype of

Vol. 14, December 2003 5063
Figure 3.

A

B
Table 2. Effects of hRap1 mutants on telomere length heterogeneity

<table>
<thead>
<tr>
<th>hRap1 allele</th>
<th>PDa</th>
<th>Median lengthb</th>
<th>50% signal intervalc</th>
<th>Heterogeneity indexd</th>
</tr>
</thead>
<tbody>
<tr>
<td>hRap1</td>
<td>0</td>
<td>1.9</td>
<td>1.7</td>
<td>0.89</td>
</tr>
<tr>
<td>hRap1AC</td>
<td>0</td>
<td>3.2</td>
<td>3.0</td>
<td>1.25</td>
</tr>
<tr>
<td>hRap1ΔBr</td>
<td>0</td>
<td>2.8</td>
<td>2.6</td>
<td>0.93</td>
</tr>
<tr>
<td>hRap1ΔBrAC</td>
<td>0</td>
<td>2.9</td>
<td>3.2</td>
<td>1.09</td>
</tr>
<tr>
<td>hRap1ΔMAC</td>
<td>0</td>
<td>2.6</td>
<td>2.9</td>
<td>1.10</td>
</tr>
<tr>
<td>pLPC</td>
<td>108</td>
<td>2.6</td>
<td>3.3</td>
<td>1.25</td>
</tr>
<tr>
<td>pLPC</td>
<td>120</td>
<td>2.6</td>
<td>2.9</td>
<td>1.13</td>
</tr>
<tr>
<td>hRap1</td>
<td>120</td>
<td>4.8</td>
<td>5.2</td>
<td>1.10</td>
</tr>
<tr>
<td>hRap1AC</td>
<td>108</td>
<td>7.7</td>
<td>6.9</td>
<td>0.90</td>
</tr>
<tr>
<td>hRap1AC</td>
<td>120</td>
<td>7.8</td>
<td>6.7</td>
<td>0.86</td>
</tr>
<tr>
<td>hRap1ΔBr</td>
<td>120</td>
<td>9.0</td>
<td>4.8</td>
<td>0.53</td>
</tr>
<tr>
<td>hRap1ΔBr</td>
<td>132</td>
<td>9.1</td>
<td>5.0</td>
<td>0.55</td>
</tr>
<tr>
<td>hRap1ΔBrΔM</td>
<td>108</td>
<td>9.7</td>
<td>4.1</td>
<td>0.47</td>
</tr>
<tr>
<td>hRap1ΔBrΔM</td>
<td>180</td>
<td>11.8</td>
<td>5.6</td>
<td>0.47</td>
</tr>
<tr>
<td>hRap1ΔMAC</td>
<td>96</td>
<td>10.0</td>
<td>7.5</td>
<td>0.75</td>
</tr>
<tr>
<td>hRap1ΔMAC</td>
<td>108</td>
<td>10.9</td>
<td>7.3</td>
<td>0.67</td>
</tr>
<tr>
<td>hRap1ΔM</td>
<td>132</td>
<td>11.6</td>
<td>9.0</td>
<td>0.78</td>
</tr>
</tbody>
</table>

a PD 0 represents the first split after selection for retroviral infection. The number of population doublings at this PD could vary slightly for different hRap1 mutants.

b Median telomere length (in kb) was determined based on telomeric restriction fragment blots by scanning through the lanes. The portion of subtelomeric DNA on telomeric restriction fragments is assumed to be 2 kb, and this length is subtracted from all values.

c 50% signal interval (in kb) represents the size distribution covering 50% of the telomeric signal (MATERIALS AND METHODS).

d The heterogeneity index represents the ratio of the 50% signal interval (fourth column) and the median telomere length (third column).

index of late PD cultures of hRap1ΔMAC that have very long telomeres (Table 2).

Telomere Length Effects of hRap1 Depend on Telomerase Expression

To determine whether the effects of hRap1 were dependent on telomerase, each of the alleles was expressed in primary human IMR90 fibroblasts and cells were passaged until they reached senescence. The telomere shortening rates revealed no discernible differences and the cells entered telomere-directed senescence at approximately the same PD (Figure 4A; our unpublished data). Overexpression of full-length and deletion versions of hRap1 also did not affect telomere length in the ALT-cell line GM847 when analyzed >102 PD (Figure 4B; our unpublished data). These data are consistent with hRap1 affecting the cis-acting telomere length control pathway that affects telomerase-mediated telomere elongation. Furthermore, we did not observe obvious changes in the telomere length distribution of primary cells and ALT cells expressing hRap1ΔBr and hRap1ΔBrΔM.

DISCUSSION

The data presented here are consistent with Rap1 functioning as a regulator of telomere length in human cells as it does in budding yeast (Conrad et al., 1990; Lustig et al., 1990; Kyrian et al., 1992; Krauskopf and Blackburn, 1996; Marcand et al., 1997a). This conserved role for Rap1 in telomere length regulation is also consistent with fission yeast experiments in which deletion of Rap1 resulted in extensive telomere elongation (Hanaoka et al., 2001; Kanoh and Ishikawa, 2001).

Based on the observation that nucleoplasmic expression of hRap1 induced telomere elongation, we speculate that hRap1, like scRap1, is a cis-acting negative regulator of telomere length. This effect was observed for two hRap1 mutants that lack the TRF2 interacting domain and do not localize to telomeres. The simplest interpretation is that these mutants titrate a limiting hRap1-interacting factor that needs to bind telomeric hRap1 to maintain a stable length setting. The fact that hRap1ΔBrΔACT can have this titration effect suggests that the BRCT domain is not the only domain involved in binding of this putative telomere length regulator. Titration of a limiting factor may also explain why full-length hRap1 induced telomere elongation. Overexpression of wild-type hRap1 in HTC75 cells also results in large amounts of nucleoplasmic protein because the telomeric TRF2 binding sites become saturated. We speculate that this nucleoplasmic pool of hRap1 competes with telomeric hRap1 for the binding of the limiting interacting partner, resulting in diminished telomere length control and longer telomeres. Similarly, an S. cerevisiae Rap1 mutant (ΔDBB) that lacks the ability to bind to telomeres induced telomere elongation (Conrad et al., 1990), presumably through titration of Rif1 and Rif2 in the nucleoplasm. However, the data presented here should be interpreted cautiously because they involve overexpression of mutant alleles that may either titrate factors in the nucleoplasm or disrupt telomere length regulatory complexes at the telomere (or both). A direct test of the idea that human Rap1 is a negative regulator of...
Telomere length may be obtained using the recently developed telomere tethering approach (Ancelin et al., 2002). An important challenge is also to identify the putative telomere length control factor that interacts with hRap1. Human Rif1 was recently identified, but there is no indication that this protein binds to hRap1 or even that it is present at telomeres (Silverman and de Lange, unpublished data). Similarly, in fission yeast, Rif1 is not a Rap1 binding factor (Kanoh and Ishikawa, 2001), and it is likely that spRap1 has other interacting partners required for telomere length control. Human or fission yeast orthologs of Rif2 have not been identified so far.

The proposal that hRap1 acts as a negative regulator of telomere length is also consistent with the strong telomere elongation phenotype of four hRap1 mutants that have retained the ability to localize to telomeres. These mutants either lack the BRCT domain or the Myb domain or both. We assume that these hRap1 mutants displace the endogenous hRap1 from telomeres and act as dominant negative alleles. According to this view, the BRCT and Myb domains of hRap1 would both be required at telomeres for full telomere length control. To test whether the mutants act as dominant negative alleles, we attempted to generate antibodies specific to the BRCT and Myb domain that would allow us to monitor the displacement of the endogenous hRap1 by the mutants. However, the resulting antibodies did not react with endogenous hRap1 on telomeres. We note that the presumed dominant negative alleles of hRap1 resemble the S. cerevisiae rap1t alleles, which bind to telomeres but fail to control telomere length (Kyrion et al., 1992).

Several hRap1 deletion mutants displayed an unexpected effect on telomere length heterogeneity. Expression of telomere targeted version of hRap1 that lacked the BRCT domain resulted in a more narrow size range of telomeres after prolonged culturing of the cells. We have considered the possibility that this phenotype is due to an effect on telomere elongation by telomerase. In both yeast and mammalian cells, telomerase elongates shorter telomeres in a cell more frequently (or more extensively) than longer telomeres (Zhu et al., 1998; Marcand et al., 1999; Ouellette et al., 2000; He-

Figure 4. Examples of lack of effect of hRap1 alleles on telomere length dynamics in telomerase negative cells. (A) Genomic blotting analysis of telomeric restriction fragments in HindIII/RsaI digested genomic DNA from pLPC vector or hRap1ΔM-infected IMR90 cells, probed with a TTAGGG repeat fragment. Passages and MW markers are indicated. (B) AluI/MboI digested genomic DNA plug from GM847 cells infected with pLPC or hRap1 full-length vector was separated by CHEF gel, and in-gel hybridization analysis of telomeric restriction fragments was carried out with an end-labeled [CCCTAA]4 oligonucleotide after in situ denaturation of the DNA.
Interestingly, in budding yeast Rap1, the Myb domain has execution of negative telomere length control (Figure 5). We have previously proposed that this change occurred in conjunction with an alteration of the telomeric DNA sequence and resulted in the loss of the TRF/Taz1-like proteins from yeast telomeres (Li et al., 2000). Proper telomere length control would thus have necessitated a rearrangement of the interaction domains, allowing Rap1 to bind to telomeric DNA and tether Rif1 and Rif2 to the telomere.

**ACKNOWLEDGMENTS**

We thank members of the de Lange laboratory for technical help and discussion. We thank Kristina Hoke for extensive editing of this manuscript. This research is supported by a National Institutes of Health grant to T.d.L. (CA 76626). B.L. was in part supported by a fellowship from the Leukemia and Lymphoma Society.

**REFERENCES**


Vol. 14, December 2003 5067


